Tweet

IMULAN’s Atopic Dermatitis And Stomatitis Technology Awarded Composition Of Matter Patent

Author: Imulan
Posted: Tuesday 24th January, 2012. 21:05:32

Imulan BioTherapeutics, LLC (IMULAN) has strengthened their intellectual property position from a recently awarded composition of matter patent. The patent was issued on IMULAN’s licensed T-cell receptor (TCR) peptide therapeutics, which are classified as immuno-biologics. IMULAN holds the global veterinary license to the TCR peptides, which are undergoing formal trials for canine atopic dermatitis and feline stomatitis. Although IMULAN has remained focused on atopy and stomatitis, they are preparing to evaluate the TCR peptides for keratoconjunctivitis sicca (dry eye), feline leukemia virus and feline immunodeficiency virus infections, fungal infections, and cancer.

The TCR peptides modulate the immune system and have been shown to restore normal T-helper cell function in a variety of models. T-helper cells can be classically divided into 3 subsets (Th1, Th2, and Th17) and produce cytokines which further drive immune responses. When T-helper cell activity gets out of balance, this can lead to a variety of diseases and conditions. Restoring this balance is a comprehensive approach to disease intervention. IMULAN’s TCR peptides have several key properties, including a long duration of effect, convenient subcutaneous administration, ease of manufacturing, and proposed applications for veterinary dermatology, ophthalmology, infectious disease, immune mediated disorders, and oncology.

The T-cell receptor peptides were discovered by immunologists examining how the immune system shifted with aging, infection, and other events. The same work revealed a series of autoantibody derived peptides that could reverse or restore the normal immune balance. This same immune shift is now known to occur in a variety of animal diseases including atopic dermatitis, stomatitis, infections, cancer, and a certain immune mediated disorders. IMULAN has identified a lead TCR peptide for canine atopic dermatitis, feline stomatitis, infections, and cancer.

This article has been viewed 213 times.

 

Comments about this article